Isabel Pablos

ORCID: 0000-0001-8052-3853
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Allergic Rhinitis and Sensitization
  • Food Allergy and Anaphylaxis Research
  • Contact Dermatitis and Allergies
  • SARS-CoV-2 and COVID-19 Research
  • Computational Drug Discovery Methods
  • Dermatology and Skin Diseases
  • Immunotherapy and Immune Responses
  • Cholinesterase and Neurodegenerative Diseases
  • Estrogen and related hormone effects
  • Chemical synthesis and alkaloids
  • Cancer Immunotherapy and Biomarkers
  • Asthma and respiratory diseases
  • Immune Response and Inflammation
  • Insects and Parasite Interactions
  • Antimicrobial Peptides and Activities
  • Influenza Virus Research Studies
  • Medicinal Plants and Neuroprotection
  • Ion Channels and Receptors
  • COVID-19 Clinical Research Studies
  • RNA and protein synthesis mechanisms
  • Inflammasome and immune disorders
  • Cancer, Stress, Anesthesia, and Immune Response
  • Inflammatory mediators and NSAID effects
  • Insect and Arachnid Ecology and Behavior

University of British Columbia
2019-2024

University of Salzburg
2016-2022

Center of Molecular Immunology (Cuba)
2014

Art v 1, Amb a 4, and Par h 1 are allergenic defensin-polyproline-linked proteins present in mugwort, ragweed, feverfew pollen, respectively. We aimed to investigate the physicochemical immunological features underlying different capacities of those allergens.Recombinant were expressed E. coli physicochemically characterized detail regarding identity, secondary structure, aggregation status. Allergenic activity was assessed by mediator releases assay, serum IgE reactivity, inhibition ELISA...

10.1111/all.13298 article EN cc-by Allergy 2017-09-27

Background and objectives: Pollens of weeds are relevant elicitors type I allergies. While many Artemisia species occur worldwide, allergy research so far has only focused on vulgaris. We aimed to characterize other prevalent regarding their allergen profiles. Materials Methods: Aqueous extracts pollen from seven were characterized by gel electrophoresis ELISA using sera mugwort pollen-allergic patients (n = 11). The cDNA sequences defensin–proline-linked proteins (DPLPs) obtained, purified...

10.3390/medicina55080504 article EN cc-by Medicina 2019-08-20

Feverfew (Parthenium hysterophorus), an invasive weed from the Asteraceae family, has been reported as allergen source. Despite its relevance, knowledge of allergens is restricted to a partial sequence hydroxyproline-rich glycoprotein. We aimed obtain entire for recombinant production and characterize feverfew pollen using proteomics immunological assays. Par h 1, defensin-proline fusion was obtained by cDNA cloning recombinantly produced in E. coli. Using two complementary proteomic...

10.1038/s41598-017-06213-z article EN cc-by Scientific Reports 2017-07-14

Allergies to lipid transfer proteins involve severe adverse reactions; thus, effective and sustainable therapies are desired. Previous attempts disrupting disulfide bonds failed maintain immunogenicity; the aim is design novel hypoallergenic Pru p 3 variants evaluate applicability for treatment of peach allergy.

10.1002/mnfr.201900336 article EN cc-by-nc Molecular Nutrition & Food Research 2019-06-17

Allergies to weed pollen including members of the Compositae family, such as mugwort, ragweed, and feverfew are spreading worldwide. To efficiently treat these newly arising allergies, allergen specific immunotherapy needs be improved. Therefore, we generated novel vaccine candidates consisting TLR5-ligand Flagellin A from Listeria major mugwort Art v 1 either wild type sequence (rFlaA:Artv1) or a hypoallergenic variant (rFlaA:Artv1hyp) with reduced IgE-binding capacity. Immune modulating...

10.1038/s41598-017-11972-w article EN cc-by Scientific Reports 2017-09-12

Background: Manifestation of respiratory allergy to American cockroach (Periplaneta americana) is prominent in the subtropical and tropical areas. However, co-existing perennial indoor inhalant allergies frequently compromise clinical diagnosis allergy, analysis sensitization pattern limited by lack Periplaneta allergens widely available for component-resolved diagnostics (CRD). Objective: To evaluate a collection previously described recombinant CRD allergy. Methods: A panel nine (Per 1-5,...

10.3389/falgy.2021.691627 article EN cc-by Frontiers in Allergy 2021-06-29

While the NGcGM3/VSSP vaccine, a preparation consisting in very small sized proteoliposomes (VSSP) obtained by incorporation of NGcGM3 ganglioside into outer membrane protein (OMP) complex Neisseria meningitides, is currently studied late stage clinical trials breast cancer and melanoma patients, mechanisms involved vaccine's antitumor effect are insufficiently understood. Here we have addressed role adaptive innate immune cells mediating protective vaccine. To this aim selected 3LL-D122...

10.4161/hv.29161 article EN Human Vaccines & Immunotherapeutics 2014-05-27

Abstract To identify and characterize roles for SARS-CoV-2 3CL pro main protease in promoting viral infection dissemination, we employed Inactive Catalytic Domain Capture proteomics to host cell interactors substrates the interactome of . Of 259 interactors, 145 were associated with cytoskeleton its organisation. We determined enzyme kinetic specificity constants 139 cut-sites 43 using a multiplex assay, identifying 29 efficiently-cleaved validating 13 as vitro , SARS-CoV-2-infected human...

10.21203/rs.3.rs-3918469/v1 preprint EN cc-by Research Square (Research Square) 2024-02-21

Cyclooxygenase (COX)-1, but preferable COX-2 catalyzes the synthesis of PGE2 in several tumors, promoting angiogenesis and a suppressive inflammation their microenvironments. Different types cancer vaccines have been combined with inhibitors, assuming that its particular mechanism action will not influence overall results combination. In this research, possible relationship between type vaccine outcome combination COX inhibitor was experimentally addressed. We investigated whether...

10.4236/jct.2017.82016 article EN Journal of Cancer Therapy 2017-01-01
Coming Soon ...